United Therapeutics Corporation (UTHR): Price and Financial Metrics

United Therapeutics Corporation (UTHR)

Today's Latest Price: $112.79 USD

0.59 (0.53%)

Updated Aug 7 6:55pm

Add UTHR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

UTHR Stock Summary

  • With a year-over-year growth in debt of -23.81%, UNITED THERAPEUTICS Corp's debt growth rate surpasses merely 12.31% of about US stocks.
  • Over the past twelve months, UTHR has reported earnings growth of -519.66%, putting it ahead of just 3.92% of US stocks in our set.
  • The volatility of UNITED THERAPEUTICS Corp's share price is greater than that of just 16.23% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to UNITED THERAPEUTICS Corp, a group of peers worth examining would be MXL, LSCC, FGEN, SMTC, and ROKU.
  • UTHR's SEC filings can be seen here. And to visit UNITED THERAPEUTICS Corp's official web site, go to www.unither.com.
UTHR Daily Price Range
UTHR 52-Week Price Range

UTHR Stock Price Chart Technical Analysis Charts

UTHR Price/Volume Stats

Current price $112.79 52-week high $127.79
Prev. close $112.20 52-week low $75.58
Day low $111.64 Volume 255,200
Day high $113.27 Avg. volume 586,471
50-day MA $117.72 Dividend yield N/A
200-day MA $102.21 Market Cap 5.01B

United Therapeutics Corporation (UTHR) Company Bio

United Therapeutics develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension. The company was founded in 1996 and is based in Silver Spring, Maryland.

UTHR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$112.79$220.03 95%

We started the process of determining a valid price forecast for UNITED THERAPEUTICS Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that UNITED THERAPEUTICS Corp ranked in the 62th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 95.67%. In terms of the factors that were most noteworthy in this DCF analysis for UTHR, they are:

  • UTHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 29.7% of tickers in our DCF set.
  • UNITED THERAPEUTICS Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 16.23. This coverage rate is greater than that of 84.59% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The weighted average cost of capital for the company is 7. This value is greater than merely 22.53% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of UNITED THERAPEUTICS Corp? See NHC, AMPH, HCSG, CBPO, and FMS.

UTHR Latest News Stream

Event/Time News Detail
Loading, please wait...

UTHR Latest Social Stream

Loading social stream, please wait...

View Full UTHR Social Stream

Latest UTHR News From Around the Web

Below are the latest news stories about UNITED THERAPEUTICS Corp that investors may wish to consider to help them evaluate UTHR as an investment opportunity.

United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat

United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

Yahoo | July 30, 2020

United Therapeutics Corp (UTHR) Q2 2020 Earnings Call Transcript

It's my pleasure to welcome you to the United Therapeutics Corporation Second Quarter 2020 Earnings Call. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairman and Chief Executive Officer; Mr. Michael Benkowitz, our President and Chief Operating Officer; Mr. James Edgemond, our Chief Financial Officer and Treasurer; and Dr. Leigh Peterson, our Vice President of Product Development.

Yahoo | July 30, 2020

United Therapeutics EPS beats by $0.41, beats on revenue

United Therapeutics (UTHR): Q2 Non-GAAP EPS of $3.68 beats by $0.41; GAAP EPS of $2.41 misses by $0.38.Revenue of $362M (-3.1% Y/Y) beats by $22.03M.Remodulin sales of $119M vs. consensus of $138.7M.Press Release...

Seeking Alpha | July 29, 2020

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q2 2020 Results - Earnings Call Transcript

United Therapeutics Corporation (UTHR) Q2 2020 Earnings Conference Call July 29, 2020 9:00 am ET Corporate Participants Dewey Steadman - Head, Investor Relations Martine Rothblatt - Chairman and Chief Operating Officer Mike Benkowitz - President and Chief Operating Officer Leigh Peterson - Vice President, Product Development Conference Call participants Hartaj...

SA Transcripts on Seeking Alpha | July 29, 2020

United Therapeutics Corporation's (NASDAQ:UTHR) Intrinsic Value Is Potentially 73% Above Its Share Price

Today we will run through one way of estimating the intrinsic value of United Therapeutics Corporation (NASDAQ:UTHR...

Yahoo | July 29, 2020

Read More 'UTHR' Stories Here

UTHR Price Returns

1-mo -3.96%
3-mo -1.28%
6-mo 7.97%
1-year 38.22%
3-year -12.04%
5-year -31.30%
YTD 28.05%
2019 -19.12%
2018 -26.39%
2017 3.15%
2016 -8.42%
2015 20.94%

Continue Researching UTHR

Want to see what other sources are saying about UNITED THERAPEUTICS Corp's financials and stock price? Try the links below:

UNITED THERAPEUTICS Corp (UTHR) Stock Price | Nasdaq
UNITED THERAPEUTICS Corp (UTHR) Stock Quote, History and News - Yahoo Finance
UNITED THERAPEUTICS Corp (UTHR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8181 seconds.